ArticleOncotarget2018

The difference in the survival rate of patients with metastatic renal cell carcinoma in the intermediate-risk group of the Memorial Sloan Kettering Cancer Center criteria.

Satoshi Tamada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.